Ubs Asset Management Americas Inc Verve Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 115,041 shares of VERV stock, worth $692,546. This represents 0.0% of its overall portfolio holdings.
Number of Shares
115,041
Previous 108,446
6.08%
Holding current value
$692,546
Previous $529,000
5.1%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding VERV
# of Institutions
186Shares Held
73.3MCall Options Held
85KPut Options Held
215K-
Alphabet Inc. Mountain View, CA12.3MShares$74.3 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$39.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$29.9 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$25.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$24.1 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $361M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...